Insulin aspart: a novel rapid-acting human insulin analogue

Bibliography

• DCCT RESEARCH GROUP: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. New Engl. J. Med. (1993) 329:977–986.
   PubMed Web of Science ®Google Scholar
• UKPDS GROUP: Intensive blood-glucose control withsulphonylureas or insulin compared with conven-tional treatment and risk of complications in patients with Type 2 diabetes (UKPDS 33). Lancet (1998) 352:837–853.
   PubMed Web of Science ®Google Scholar
• UKPDS GROUP: Effect of intensive blood-glucosecontrol with metformin on complications in overweight patients with Type 2 diabetes (UKPDS 34). Lancet (1998) 352:854–865.
   PubMed Web of Science ®Google Scholar
• BLUNDELL T, DODSON G, HODGKIN D, MERCOLA D:Insulin: the structure in the crystal and its reflection in chemistry and biology. Adv. Protein Chem. (1972) 26:279–402.
   Google Scholar
• KAARSHOLM NC, LUDVIGSEN S: The high resolution solution structure of the insulin monomer determined by NMR. Receptor (1995) 5:1–8.
   PubMedGoogle Scholar
• EMDIN SO, DODSON GG, CUTFIELD JM, CUTFIELD SM: Role of zinc in insulin biosynthesis. Some possible zinc-insulin interactions in the pancreatic B-cell. Diabetologia (1980) 19:174–182.
   Google Scholar
• BRANGE J: Galenics of Insulin: the physico-chemical and pharmaceutical aspects of insulin and insulin preparations. Springer Verlag, Berlin (1987).
   Google Scholar
• GAMMELTOFT S: Insulin receptors: binding kinetics and structure-function relationship of insulin. Physiol Rev. (1984) 64:1321–1378.
   PubMed Web of Science ®Google Scholar
• BRANGE J, OWENS DR, KANG S, VOLUND A: Monomericinsulins and their experimental and clinical implica-tions. Diabetes Care (1990) 13:923–954.
   PubMed Web of Science ®Google Scholar
• BRANGE J, RIBEL U, HANSEN JF et al: Monomeric insulins obtained by protein engineering and their medical implications. Nature (1988) 333:679–682.
   PubMed Web of Science ®Google Scholar
• WHITTINGHAM JL, EDWARDS DJ, ANTSON AA, CLARKSON JM, DODSON GG: Interactions of phenol and m-cresol in the insulin hexamer, and their effect on the association properties of B28 pro-* Asp insulin analogues. Biochemistry (1998) 37:11516–11523.
   PubMed Web of Science ®Google Scholar
• BRANGE J, VOLUND A: Insulin analogs with improvedpharmacokinetic profiles. Adv. Drug Deliv. Rev. (1999) 35:307–335.
   PubMed Web of Science ®Google Scholar
• BREMS DN, ALTER LA, BECKAGE MJ et al: Altering the association properties of insulin by amino acid replacement. Protein Eng. (1992) 5:527–533.
   PubMedGoogle Scholar
• KASUGA M, ZICK Y, BLITHE DL, CRETTAZ M, KAHN CR: Insulin stimulates tyrosine phosphorylation of the insulin receptor in a cell-free system. Nature (1982) 298:667–669.
   PubMed Web of Science ®Google Scholar
• KASUGA M, KARLSSON FA, KAHN CR: Insulin stimulatesthe phosphorylation of the 95,000-dalton subunit of its own receptor. Science (1982) 215:185–187.
   PubMed Web of Science ®Google Scholar
• CHEATHAM B, KAHN CR: Insulin action and the insulin signaling network. Endocr. Rev. (1995) 16:117–142.
   PubMed Web of Science ®Google Scholar
• ULLRICH A, GRAY A, TAM AW et al: Insulin-like growth Factor I receptor primary structure: comparison with insulin receptor suggests structural determinants that define functional specificity. EMBO J. (1986) 5:2503–2512.
   PubMed Web of Science ®Google Scholar
• DE-MEYTS P: The structural basis of insulin and insulin-like growth factor-I receptor binding and negative co-operativity, and its relevance to mitogenic versus metabolic signalling. Diabetologia (1994) 37:S135–S148
   PubMedGoogle Scholar
• PULLEN RA, LINDSAY DG, WOOD SP et al: Receptor-binding region of insulin. Nature (1976) 259:369–373.
   PubMed Web of Science ®Google Scholar
• KURTZHALS P, SCHAFFER L, DREJER K, HANSEN BF: Insulin receptor tyrosine kinase activation by insulin aspart and insulin analogues with a wide range of receptor binding affinities. Diabetologia (1999) 42 (Suppl. 1):A179.
   Google Scholar
• SLIEKER LJ, BROOKE GS, DIMARCHI RD et al: Modifica-tions in the B10 and B26-30 regions of the B chain of human insulin alter affinity for the human IGF-I receptor more than for the insulin receptor. Diabetologia (1997) 40:S54–S61.
   PubMed Web of Science ®Google Scholar
• TRIIB T, HEY A, SORENSEN AR et al.: Growth promoting activity of insulin aspart and other insulin analogues. Diabetologia (1999) 42 (Suppl. 1) :A179.
   Google Scholar
• RODAN SB, WESOLOWSKI G, IANACONE J, THIEDE MA,RODAN GA: Production of parathyroid hormone-like peptide in a human osteosarcoma cell line: stimula-tion by phorbol esters and epidermal growth factor. J. Endocrinol. (1989) 122:219–227.
   PubMed Web of Science ®Google Scholar
• HANSEN BF, DANIELSEN GM, DREJER K et al.: Sustained signalling from the insulin receptor after stimulation with insulin analogues exhibiting increased mitogenic potency. Biochem. J. (1996) 315:271–279.
   PubMed Web of Science ®Google Scholar
• DREJER K, KRUSE V, LARSEN UD et al: Receptor binding and tyrosine kinase activation by insulin analogues with extreme affinities studied in human hepatoma HepG2 cells. Diabetes (1991) 40:1488–1495.
   PubMed Web of Science ®Google Scholar
• BORNFELDT KE, GIDLOF RA, WASTESON A et al.: Binding and biological effects of insulin, insulin analogues and insulin-like growth factors in rat aortic smooth muscle cells. Comparison of maximal growth promoting activities. Diabetologia (1991) 34:307–313.
   Google Scholar
• DALL V: Preclinical safety pharmacology studies on the rapid-acting insulin analogue insulin aspart. Arzneimittel-Forschung/Drug Research (1999) 49 (0:463–470.
   PubMedGoogle Scholar
• SHER SP, JENSEN RD, BOKELMAN DL: Spontaneous tumors in control F344 and charles river-CD rats and Charles River CD-1 and B6C3HF1 mice. Toxicol Lett. (1982) 11:103–110.
   PubMed Web of Science ®Google Scholar
• GRICE H, CIMINERA JL: Carcinogenicity. The design,analysis and interpretation of long-term animal studies. Springer Verlag, Berlin (1988).
   Google Scholar
• ZIMMERMANN J: A 12-month chronic toxicity study ofly275585 (human insulin analog) administered subcutaneously to fischer-344 rats. Diabetes (1994) 43:A166–A166
   Web of Science ®Google Scholar
• DREJER K: The bioactivity of insulin analogues from in vitro receptor binding to in vivo glucose uptake. Diabetes Metab. Rev. (1992) 8:259–285.
   PubMed Web of Science ®Google Scholar
• HEINEMANN L, HEISE T, JORGENSEN LN, STARKE AA: Action profile of the rapid acting insulin analogue: human insulin B28Asp. Diabel Med. (1993) 10:535–539.
   PubMed Web of Science ®Google Scholar
• HEINEMANN L, KAPITZA C, STARKE AA, HEISE T: Time-action profile of the insulin analogue B28Asp. Diabet. Med. (1996) 13:683–684.
   PubMed Web of Science ®Google Scholar
• HOME PD, BARRIOCANAL L, LINDHOLM A: Comparative pharmacokinetics and pharmacodynamics of the novel rapid-acting insulin analogue, insulin aspart, in healthy volunteers. Eur. J. Clin. Pharmacol. (1999) 55:199–203.
   PubMed Web of Science ®Google Scholar
• HOME PD, LINDHOLM A, HYLLEBERG B, ROUND P: Improved glycaemic control with insulin aspart: A multicenter randomized double-blind crossover trial in Type 1 diabetic patients. Diabetes Care (1998) 21: 1904-1909.
   Google Scholar
• LINDHOLM A, MCEWEN J, RIIS AP: Improved postpran-dial glycaemic control with insulin aspart: A random-ized double-blind cross-over trial in Type 1 diabetes. Diabetes Care (1999) 22:801–805.
   PubMed Web of Science ®Google Scholar
• RASKIN P, JOVANOVIC L, GUTHRIE RA, LETTER L, BOSS AH: Insulin aspart improves glycaemic control compared to human insulin for patients with Type 1 diabetes. Diabetes (1999) 48 (Supp1.1) :A115
   Google Scholar
• HOME PD, LINDHOLM A, RIIS P: Improved long-term blood glucose control with insulin aspart versus human insulin in people with Type 1 diabetes. Diabetes (1999) 48 (Supp1.1) :A358
   Google Scholar
• HOOGWERF B, RASKIN P, JOVANOVIC L et al: Insulin aspart - a mealtime alternative to soluble human insulin in Type 1 diabetes. Diabetologia (1999) 42 (Supp1.1) :A237.
   Google Scholar
• REID TW, REID WA: The labile nature of the insulinsignal(s) for the stimulation of DNA synthesis in mouse lens epithelial and 3T3 cells. J. Biol. Chem. (1987) 262:229–233.
   PubMed Web of Science ®Google Scholar
• MILAZZO G, SCIACCA L, PAPA V, GOLDFINE ID, VIGNERI R: ASPB10 insulin induction of increased mitogenic responses and phenotypic changes in human breast epithelial cells: evidence for enhanced interactions with the insulin-like growth factor-I receptor. Mol Carcinog. (1997) 18:19–25.
   PubMed Web of Science ®Google Scholar
• ODUM J, TITTENSOR S, ASHBY J: Limitations of the mcf-7 cell-proliferation assay for detecting xenobiotic estrogens. Tox. Vitro (1998) 12:273–278.
   PubMed Web of Science ®Google Scholar
• HOME P: Insulin glargine: The first clinically useful extended-acting insulin in half a century? Exp. Opin. Invest. Drugs (1999) 8:307–314.
   Google Scholar
• SEIPKE G, BERCHTHOLDT H, GEISEN K, HILGENFELD R, ROSSKAMP R: HOE901 - a new insulin with prolonged action. Eur. J. Endocrinol (1995) 132 (Supp1.1) :25
   Google Scholar
• BERTI L, KELLERER M, BOSSENMAIER B et al.: The long acting human insulin analog HOE 901: Characteristics of insulin signalling in comparison to Asp(B10) and regular insulin. Horm. Metab. Res. (1998) 30:123–129.
   PubMed Web of Science ®Google Scholar
• BAHR M, KOLTER T, SEIPKE G, ECKEL J: Growth promoting and metabolic activity of the human insulin analogue [Gly(A21),Arg(B31),Arg(B32)]insulin (HOE 901) in muscle cells. Eur. J. Pharmacol. (1997) 320:259–265.
   PubMed Web of Science ®Google Scholar